FDA clears amivantamab combination for head and neck cancer

The US Food and Drug Administration granted accelerated approval to amivantamab combined with recombinant human hyaluronidase-lpuj for adults with recurrent or metastatic head and neck squamous cell carcinoma whose disease progressed on or after platinum-based chemotherapy. The decision provides a specific biological alternative for advanced cases that have exhausted frontline cytotoxic regimens.

Head and neck squamous cell carcinoma accounts for roughly 90 percent of all head and neck malignancies globally. Platinum-resistant forms carry poor prognoses, historically leaving individuals with few therapeutic options beyond toxic palliative chemotherapies that erode baseline physical capacity and metabolic health.

Amivantamab functions as a bispecific antibody directed against epidermal growth factor (EGFR) and mesenchymal-epithelial transition (MET) receptors. Hyaluronidase temporarily degrades local hyaluronan in subcutaneous tissue, allowing direct subcutaneous injection rather than protracted intravenous infusions that consume entire days in infusion suites.

When you evaluate advanced oncology interventions with your medical team, demand full visibility into the receptor profile of your biopsy. Treat biological data as your baseline baseline; tracking molecular markers gives you concrete grounds to discuss whether targeted subcutaneous interventions fit your specific pathology.